IINN
Inspira Technologies Oxy B.H.N. Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.74
P/S
34.26
EV/EBITDA
-1.01
DCF Value
$0.11
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.7%
Operating Margin
2503.5%
Net Margin
-2213.8%
ROE
-278.1%
ROA
-119.8%
ROIC
258.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $289.0K | $-13.2M | $-0.45 |
| Q2 2025 | $144.5K | $-3.2M | $-0.12 |
| Q1 2025 | $144.5K | $-3.2M | $-0.12 |
| FY 2024 | $0.00 | $-11.1K | $-0.00 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
2.33
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.